^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
BL0020
i
Other names: BL0020
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Shanghai Best-Link Biosci
Drug class:
Topoisomerase I inhibitor
Related drugs:
2years
Phase I Study of BL0020, a Novel Anti-tumor Drug, in Adult Subjects With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=66, Recruiting, Shanghai Best-Link Bioscience, LLC | Not yet recruiting --> Recruiting
Enrollment open
|
BL0020
2years
Phase I Study of BL0020, a Novel Anti-tumor Drug, in Adult Subjects With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=66, Not yet recruiting, Shanghai Best-Link Bioscience, LLC | Initiation date: Jul 2023 --> Oct 2023
Trial initiation date • Metastases
|
BL0020
over2years
Phase I Study of BL0020, a Novel Anti-tumor Drug, in Adult Subjects With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=66, Not yet recruiting, Shanghai Best-Link Bioscience, LLC
New P1 trial • Metastases
|
BL0020
Share via
